Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study

Affiliations

Comment

Pasquale Niscola. Lancet Haematol. 2025 Feb.

. 2025 Feb;12(2):e88-e90.

doi: 10.1016/S2352-3026(24)00355-7.

¹ Hematology Unit, S Eugenio Hospital, Rome 00122, Italy. Electronic address: pniscola@gmail.com.

No abstract available

Conflict of interest statement

I declare no competing interests.

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study.
Garelius HKG, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, Mittelmann M, Stauder R, Čermák J, Sanz G, Langemeijer S, Malcovati L, Germing U, Sanhes L, d'Aveni M, Culligan D, Kotsianidis I, Koinig KA, van Marrewijk C, Crouch S, deWitte T, Smith A, Hellström-Lindberg E. Garelius HKG, et al. Lancet Haematol. 2025 Feb;12(2):e128-e137. doi: 10.1016/S2352-3026(24)00350-8. Lancet Haematol. 2025. PMID: 39909656 Free PMC article.